Genetic engineering of tumor-infiltrating monocytes to inhibit primary and metastatic breast cancer

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1083747

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The immunosuppressive environment within a tumour is the major impediment to the successful application of cancer immunotherapy. To address this, we developed a cell- and gene-based strategy for targeted delivery of a potent immune-stimulatory molecule, IFN-?, which activates the immune response at the site of the tumour. We now propose to combine this strategy with promising cancer immunotherapies for the treatment of advanced breast cancer and breast cancer metastasis.

Funded Activity Details

Start Date: 01-01-2015

End Date: 01-01-2018

Funding Scheme: Project Grants

Funding Amount: $792,470.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cancer immunotherapy | cancer metastasis | cancer therapy | macrophages | tumour targeting

Related Links